📈 Rossari Biotech Q1 Update: Steady Growth Amid Margin Pressure

🔑 Key Financial Highlights ✅ Consolidated Net Profit rises to ₹35 Cr in Q1 FY24, up from ₹33.6 Cr YoY ✅ Revenue climbs sharply to ₹697 Cr, marking a robust 28% growth compared to ₹543 Cr last year ✅ EBITDA improves to ₹80.6 Cr, a 19% increase YoY, though EBITDA margin narrows to 11.56% from 12.5% 🔍 What’s Behind the Numbers? - Strong top-line growth driven by expanded product mix and market demand - Margin compression reflects higher input costs and operational expenses, a common challenge in the specialty chemicals sector 📊 Did you know? Despite margin pressure, Rossari’s consistent profit growth signals resilient business fundamentals in the competitive Indian biotech space.